Mr. Figg is a principal in the Washington, DC law firm of Rothwell, Figg, Ernst & Manbeck. He specializes in intellectual property law, primarily involving the chemical, pharmaceutical, healthcare and biotechnology industries. His practice focuses on patent litigation and interferences, patent procurement, intellectual property licensing and related contract matters, opinions and counseling.Mr. Figg has served as lead counsel in a large number of complex patent litigations in federal district courts, the International Trade Commission, and the Board of Patent Appeals and Interferences, as well as appeals before the United States Court of Appeals for the Federal Circuit and the Court of Appeals for the District of Columbia Circuit. Brief synopses of many of these cases may be found at his firm's website.Mr. Figg litigated some of the first cases arising out of the Drug Price Competition and Patent Term Restoration Act of 1984 (the so-called "Hatch-Waxman amendments) and has continued to handle a large number of such cases. His trial and appellate practice have included the successful prosecution of a number of groundbreaking cases involving the interpretation and application of the Hatch-Waxman amendments. Included among these is his representation of Burroughs Wellcome Co. in federal district courts and the Federal Circuit in connection with challenges to its patents covering the first successful AIDS drug, AZT (Retrovir®). He has served as lead counsel for Mylan Pharmaceuticals in numerous patent infringement actions and administrative law cases involving the FDA, including litigations with Bristol-Myers which established for the first time the potential for antitrust liability in connection with improper listing of patents in the FDA's Orange Book. Mr. Figg also served as lead counsel for Zeneca Inc. (now AstraZeneca) in federal district court and the Federal Circuit in an action relating to its highly successful cancer drug, Casodex.